Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

66.7%

2 terminated/withdrawn out of 3 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 1(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT03038828Phase 1Terminated

Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts

Role: lead

NCT01265849Phase 3Completed

Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

Role: lead

NCT02115919Phase 1Terminated

Safety Study of Multikine in the Treatment of Perianal Warts

Role: collaborator

All 3 trials loaded